Tonix Pharmaceuticals Hld

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Alset EHome International

Vyne Therapeutics

Are these under $1 penny stocks worth buying this month? The post 3 Penny Stocks Under $1 That Are on Fire Today  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks Under $1 That Are on Fire Today

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has enrolled the first patient in the new Phase 3 RESILIENT study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the management of fibromyalgia. An interim analysis by an Independent Data Monitoring Committee of.

Tonix Pharma Starts New Pivotal Trial For TNX-102 SL In Fibromyalgia Patients

Advent Technologies Holdings

Are these under $4 penny stocks on your buy list right now? The post Best Penny Stocks to Buy For Under $4 in Early April?

Best Penny Stocks to Buy For Under $4 in Early April? 3 to Watch

Phase 2 Clinical Trial of TNX-102 SL for the Treatment of Long COVID Expected to Start Second Quarter 2022

Tonix Pharmaceuticals Announces IND Clearance for TNX-102 SL as a Potential Treatment for Long COVID Syndrome, Also Known as Post-Acute Sequelae of COVID-19 (PASC)

Ardelyx

Ocugen, Inc.

Can these biotech penny stocks continue to make gains? The post Hot Biotech Penny Stocks to Watch During the First Full Week of April  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Hot Biotech Penny Stocks to Watch During the First Full Week of April

Jaguar Health

BitNile Holdings

Check these 3 penny stocks out for your watchlist this month The post Are Penny Stocks Worth Investing In This Month? 3 To Watch Under $1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Are Penny Stocks Worth Investing In This Month? 3 To Watch Under $1

Color Star Technology

Wish

Are these penny stocks on your watchlist right now or not? The post 3 Penny Stocks That You Need to Add to Your List This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks That You Need to Add to Your List This Week

Butler National Corporation

NexImmune

Performant Financial

Ricebran Technologies

The Dow Jones jumped around 200 points on Tuesday. Investors, meanwhile, focused on some notable insider trades.

Executives Buy More Than $1M Of 5 Penny Stocks

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) says that as expected, TNX-102 SL (cyclobenzaprine HCl sublingual tablets) did not significantly reduce fibromyalgia daily pain at Week 14 compared to placebo in the Phase 3 RALLY study.  Tonix reported interim analysis.

Tonix Says Fibromyalgia Candidate Failed To Achieve Statistical Significance Over Placebo

As Expected Based on Interim Analysis Results Reported in July 2021, TNX-102 SL Did Not Achieve Statistical Significance Over Placebo on the Primary Endpoint of Reduction in Daily Pain in RALLY Study

Tonix Pharmaceuticals Announces Phase 3 RALLY Study Results for TNX-102 SL 5.6 mg for the Management of Fibromyalgia

Even a series of reverse share splits couldn't prop TNXP stock up for very long, so don't get caught in this dangerous value trap. The post Tonix Pharmaceuticals Stock Belongs in the Biotech Dustbin appeared first on InvestorPlace.

Tonix Pharmaceuticals Stock Belongs in the Biotech Dustbin

Immunology and CNS Programs Entering the Clinic in 2022 for Organ Transplantation, Cocaine Intoxication, Fibromyalgia, PTSD, Migraine Headache and Binge Eating Disorder

Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

CHATHAM, N.J., March 09, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Rosenfeld, Ph.D., as its new Executive Director, Genomics and Bioinformatics. In this role, Dr. Rosenfeld will direct Tonix's pharmacogenomics efforts including applying artificial intelligence, genome-wide association studies and mathematical modeling techniques to the analysis of patient outcomes in Tonix's clinical trials.

Tonix Pharmaceuticals Announces Appointment of Jeffrey Rosenfeld, Ph.D., as Executive Director, Genomics and Bioinformatics

Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) has announced an agreement with Massachusetts General Hospital to evaluate TNX-1900 (intranasal potentiated oxytocin) in a Phase 2 trial as a potential treatment for binge eating disorder.  The Phase 2 clinical trial is expected.

Tonix Pharma Collaborates With Massachusetts General Hospital For TNX-1900 In Binge Eating Disorder

An Investigator Initiated Phase 2 Clinical Trial of TNX-1900 In Patients with Binge Eating Disorder Planned for Second Half 2022

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Evaluate TNX-1900 (Intranasal Potentiated Oxytocin) for Treating Binge Eating Disorder

Buyers are unwinding their trades in a big way, following through on the profit-taking they initiated yesterday.

Why Tonix Pharmaceuticals Is Down 19% Today

The company wins orphan drug designation for one of its pipeline programs.

Why Tonix Pharmaceuticals Rocketed 33% Higher Today

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) shares are rallying higher Thursday after the company announced the FDA has granted Orphan-Drug Designation for TNX-2900 for the treatment of Prader-Willi syndrome. The co-exclusive license allows Tonix to expand its intranasal potentiated oxytocin.

Tonix Pharmaceuticals Rockets Higher Thursday: Why Is The Penny Stock Flying?

Here's the big news that's driving shares of Tonix Pharmaceuticals' TNXP stock more than 40% higher on a mixed day in the markets. The post Why Is Tonix Pharmaceuticals (TNXP) Stock Up Today?

Why Is Tonix Pharmaceuticals (TNXP) Stock Up Today?

Imperial Petroleum

What you need to know about trading penny stocks on March 3rd The post Trading Penny Stocks? Top Stock Market News for March 2nd, 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks? Top Stock Market News for March 2nd, 2022

CHATHAM, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan-Drug Designation for TNX-2900* (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome.

Tonix Pharmaceuticals Announces FDA Orphan-Drug Designation for TNX-2900 for the Treatment of Prader-Willi Syndrome

Tonix is Developing TNX-2900 (Intranasal Potentiated Oxytocin) for the Treatment of Prader-Willi in Adolescents and Adults with Hyperphagia or Excessive Eating

Tonix Pharmaceuticals Announces Research Agreement with the French National Institute of Health and Medical Research (Inserm) to Study the Mechanism of Oxytocin-Mediated Improvement of Eating Behaviors in Prader-Willi Mice

Bitfarms Ltd

Castor Maritime Inc

Kaival Brands Innovations Group

Are these penny stocks on your watchlist right now? The post Best Penny Stocks to Buy Right Now?

Best Penny Stocks to Buy Right Now? 4 to Watch in Mid-February

Potential Uses Include: Biomarker of Immunity to SARS-CoV-2; Personalized Approach to Timing COVID-19 Vaccine Boosters; Public Health Surveillance; and Serving as an Endpoint for COVID-19 Vaccine Trials

Tonix Pharmaceuticals Initiates Enrollment in Clinical Trial of TNX-2100, a Diagnostic Skin Test to Measure Functional T Cell Immunity to SARS-CoV-2

CHATHAM, N.J., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, will participate in the H.C. Wainwright BioConnect Conference and the Biotech Showcase 2022, both being held virtually.

Tonix Pharmaceuticals to Participate in Upcoming January Conferences

News for Tonix Pharmaceuticals Hld Stock (TNXP)